EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dihydromyricetin supplementation improves ethanol-induced lipid accumulation and inflammation

Isis Janilkarn-Urena, Alina Idrissova, Mindy Zhang, Masha VanDreal, Neysa Sanghavi, Samantha G Skinner, Sydney Cheng, Zeyu Zhang, Junji Watanabe, Liana Asatryan, Enrique Cadenas, Daryl L Davies

Frontiers in Nutrition · 23.08.2023 · 10

DOI: 10.3389/fnut.2023.1201007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Nutrition, online erschienen am 23.08.2023. Verfasst von Isis Janilkarn-Urena und 11 weiteren Autor:innen. Beteiligte Einrichtung: Titus Family Department of Clinical Pharmacy, University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Los An…. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Excessive alcohol consumption leads to a myriad of detrimental health effects, including alcohol-associated liver disease (ALD). Unfortunately, no available treatments exist to combat the progression of ALD beyond corticosteroid administration and/or liver transplants. Dihydromyricetin (DHM) is a bioactive polyphenol and flavonoid that has traditionally been used in Chinese herbal medicine for its robust antioxidant and anti-inflammatory properties. It is derived from many plants, including Hovenia dulcis and is found as the active ingredient in a variety of popular hangover remedies. Investigations utilizing DHM have demonstrated its ability to alleviate ethanol-induced disruptions in mitochondrial and lipid metabolism, while demonstrating hepatoprotective activity.

Methods

Female c57BL/6J mice ( n = 12/group) were treated using the Lieber DeCarli forced-drinking and ethanol (EtOH) containing liquid diet, for 5 weeks. Mice were randomly divided into three groups: (1) No-EtOH, (2) EtOH [5% (v/v)], and (3) EtOH [5% (v/v)] + DHM (6 mg/mL). Mice were exposed to ethanol for 2 weeks to ensure the development of ALD pathology prior to receiving dihydromyricetin supplementation. Statistical analysis included one-way ANOVA along with Bonferroni multiple comparison tests, where p ≤ 0.05 was considered statistically significant.

Results

Dihydromyricetin administration significantly improved aminotransferase levels (AST/ALT) and reduced levels of circulating lipids including LDL/VLDL, total cholesterol (free cholesterol), and triglycerides. DHM demonstrated enhanced lipid clearance by way of increased lipophagy activity, shown as the increased interaction and colocalization of p62/SQSTM-1, LC3B, and PLIN-1 proteins. DHM-fed mice had increased hepatocyte-to-hepatocyte lipid droplet (LD) heterogeneity, suggesting increased neutralization and sequestration of free lipids into LDs. DHM administration significantly reduced prominent pro-inflammatory cytokines commonly associated with ALD pathology such as TNF-α, IL-6, and IL-17.

Discussion

Dihydromyricetin is commercially available as a dietary supplement. The results of this proof-of-concept study demonstrate its potential utility and functionality as a cost-effective and safe candidate to combat inflammation and the progression of ALD pathology.

Schlagwörter

Stichwörter der Autor:innen

Dihydromyricetinethanolflavonoidsinflammationlipidslipophagypolyphenols

Autor:innen und Institutionen

  • Titus Family Department of Clinical Pharmacy, University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles, CA, United States.
  • Translational Research Lab, USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, United States.
  • Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

Zitieren

APA

Janilkarn-Urena, I., Idrissova, A., Zhang, M., VanDreal, M., Sanghavi, N., Skinner, S. G., Cheng, S., Zhang, Z., Watanabe, J., Asatryan, L., Cadenas, E., & Davies, D. L. (2023). Dihydromyricetin supplementation improves ethanol-induced lipid accumulation and inflammation. Frontiers in Nutrition, 10. https://doi.org/10.3389/fnut.2023.1201007

Vancouver

Janilkarn-Urena I, Idrissova A, Zhang M, VanDreal M, Sanghavi N, Skinner SG, et al. Dihydromyricetin supplementation improves ethanol-induced lipid accumulation and inflammation. Frontiers in Nutrition. 2023;10. doi:10.3389/fnut.2023.1201007

BibTeX
@article{JanilkarnUrena2023,
  author = {Janilkarn-Urena, Isis and Idrissova, Alina and Zhang, Mindy and VanDreal, Masha and Sanghavi, Neysa and Skinner, Samantha G and Cheng, Sydney and Zhang, Zeyu and Watanabe, Junji and Asatryan, Liana and Cadenas, Enrique and Davies, Daryl L},
  title = {Dihydromyricetin supplementation improves ethanol-induced lipid accumulation and inflammation},
  journal = {Frontiers in Nutrition},
  year = {2023},
  volume = {10},
  doi = {10.3389/fnut.2023.1201007}
}
Kostenlos starten →